London, England, United Kingdom In 2010 was created Advent Life Sciences, which is appeared as VC. The company was established in Europe in United Kingdom. The main office of represented VC is situated in the London.
We also calculated 8 valuable employees in our database.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Advent Life Sciences, startups are often financed by Advent Venture Partners, Index Ventures, Sofinnova Investments. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Sofinnova Investments, SR One. In the next rounds fund is usually obtained by Gilde Healthcare, Advent Venture Partners, OrbiMed.
Among the most successful fund investment fields, there are Biopharma, Medical. The fund has exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. Among the most popular portfolio startups of the fund, we may highlight Algeta, Acutus Medical, F2G. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
Opposing the other organizations, this Advent Life Sciences works on 2 percentage points more the average amount of lead investments. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 deals per year. The top amount of exits for fund were in 2018. Speaking about the real fund results, this VC is 21 percentage points more often commits exit comparing to other organizations.
Related Funds
| Fund Name | Location |
| AbbVie | Chicago, Illinois, United States |
| Changshang Kunzhong | - |
| Checkr | California, San Francisco, United States |
| CloudWise | Beijing, Beijing, China |
| Emaar | Dubai, United Arab Emirates |
| Haniel | Duisburg, Germany, Nordrhein-Westfalen |
| In Capital | China, Hangzhou, Zhejiang |
| Journey Ventures | Israel, Tel Aviv, Tel Aviv District |
| Krantz Holdings | Beverly Hills, California, United States |
| Miele Venture | - |
| Newlight Partners | New York, New York, United States |
| Old Willow Partners | Minnesota, Northfield, United States |
| Prisma Capital | Brazil, Itaim, Minas Gerais |
| Redwood Venture Partners | California, Los Altos, United States |
| Sofipaca | Aix-en-Provence, France, Provence-Alpes-Côte d'Azur |
| SRB Management | Dallas, Texas, United States |
| Swiss Investment group | - |
| Trilogy Ventures China | Beijing, Beijing, China |
| Urca Angels | Brazil, São Paulo, Sao Paulo |
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Epitopea | 24 Oct 2024 | Cambridge, Cambridgeshire, United Kingdom | |||
Beacon Therapeutics | $170M | 03 Jun 2024 | London, England, United Kingdom | ||
Curve Therapeutics | $55M | 27 Feb 2024 | Southampton, Hampshire, United Kingdom | ||
PIC Therapeutics | $35M | 19 Oct 2022 | Massachusetts, United States | ||
Moximed | $40M | 16 Aug 2022 | Hayward, California, United States | ||
MiroBio | $109M | 29 Jun 2022 | Oxford, England, United Kingdom | ||
Wondr Medical | $16M | 28 Jun 2022 | London, England, United Kingdom | ||
Epitopea | $14M | 25 Apr 2022 | Cambridge, Cambridgeshire, United Kingdom | ||
AviadoBio | $80M | 02 Dec 2021 | London, England, United Kingdom |
– Aura Biosciences closed an oversubscribed $80m financing.
– The financing was led by Matrix Capital Management and Surveyor Capital (a Citadel company) with participation from new investors, including Rock Springs Capital, Adage Capital Management LP and Velosity Capital.
– Existing investors Medicxi, Advent Life Sciences, Lundbeckfonden Ventures, Arix Bioscience, Chiesi Ventures, Ysios Capital and Columbus Venture Partners also participated in the round.
– Amphista Therapeutics from Glasgow, Scotland, UK, raised $53m in Series B funding.
– The round was co-led by Forbion and Gilde Healthcare with participation from Novartis Venture Fund, and Eli Lilly and Company, and existing investor BioMotiv and founding investor Advent Life Sciences.
– The new investment will be used to accelerate the company’s pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and to extend its proprietary TPD platform.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Epitopea | 24 Oct 2024 | Cambridge, Cambridgeshire, United Kingdom | |||
Beacon Therapeutics | $170M | 03 Jun 2024 | London, England, United Kingdom | ||
Curve Therapeutics | $55M | 27 Feb 2024 | Southampton, Hampshire, United Kingdom | ||
PIC Therapeutics | $35M | 19 Oct 2022 | Massachusetts, United States | ||
Moximed | $40M | 16 Aug 2022 | Hayward, California, United States | ||
MiroBio | $109M | 29 Jun 2022 | Oxford, England, United Kingdom | ||
Wondr Medical | $16M | 28 Jun 2022 | London, England, United Kingdom | ||
Epitopea | $14M | 25 Apr 2022 | Cambridge, Cambridgeshire, United Kingdom | ||
AviadoBio | $80M | 02 Dec 2021 | London, England, United Kingdom |
